{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-013566","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2022-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.166619+00:00","generated_at":"2026-06-23T04:33:46.327261+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenax Therapeutics announces positive oral levosimendan data in PH-HFpEF patients at HFSA meeting","bullets":["18 PH-HFpEF patients transitioned from IV to oral levosimendan with no serious adverse events reported.","6-minute walk distance improved by mean 13.1 m; BNP decreased by mean 133.3 pg/dL; NT-proBNP decreased by 239.4 pg/dL.","KCCQ overall summary score improved 3.7 points; physical and clinical summary scores also improved.","Oral formulation at 3-4 mg/day deemed safe and effective for chronic use, supporting Phase 3 testing.","Data presented at HFSA Scientific Sessions 2022; investigators concluded oral levosimendan is well tolerated."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-013566","json":"https://secwatch.observer/filing/0001654954-22-013566.json","markdown":"https://secwatch.observer/filing/0001654954-22-013566.md","text":"https://secwatch.observer/filing/0001654954-22-013566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495422013566/0001654954-22-013566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495422013566/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:33:46.327261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}